Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia

Joseph Patrick McEvoy, M. McCue, S. Freter

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Anticholinergic drugs have been shown to impair new memory acquisition. In a double-blind study, 22 chronically schizophrenic patients had the anticholinergic drugs that they had been taking to control the extrapyramidal side effects (EPSE) of neuroleptic drugs discontinued and were randomly assigned to treatment either with benztropine (an anticholinergic) or with amantadine (which has little or no anticholinergic effect). The EPSE of five of the ten patients assigned to amantadine could not be adequately controlled with that drug alone, and these patients were withdrawn from the study prematurely. The five patients who completed the six-week trial on amantadine showed improved performance on tests of memory acquisition in comparison with patients treated with benztropine. Global inspection of the results showed that only 36% of the patients taking benztropine showed improvement in memory acquisition at the four- and six-week assessments, whereas 80% of the amantadine users showed improvement at the four-week assessment. Analysis of covariance, however, revealed that the performance of the latter group decreased almost to baseline at six weeks, as an additional two of the remaining patients developed distressing EPSE.

Original languageEnglish (US)
Pages (from-to)429-433
Number of pages5
JournalClinical Therapeutics
Volume9
Issue number4
StatePublished - Jan 1 1987
Externally publishedYes

Fingerprint

Amantadine
Cholinergic Antagonists
Schizophrenia
Outpatients
Benztropine
Pharmaceutical Preparations
Drug-Related Side Effects and Adverse Reactions
Double-Blind Method
Antipsychotic Agents

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia. / McEvoy, Joseph Patrick; McCue, M.; Freter, S.

In: Clinical Therapeutics, Vol. 9, No. 4, 01.01.1987, p. 429-433.

Research output: Contribution to journalArticle

@article{4a98c07e7849401485ed27de025ce6ac,
title = "Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia",
abstract = "Anticholinergic drugs have been shown to impair new memory acquisition. In a double-blind study, 22 chronically schizophrenic patients had the anticholinergic drugs that they had been taking to control the extrapyramidal side effects (EPSE) of neuroleptic drugs discontinued and were randomly assigned to treatment either with benztropine (an anticholinergic) or with amantadine (which has little or no anticholinergic effect). The EPSE of five of the ten patients assigned to amantadine could not be adequately controlled with that drug alone, and these patients were withdrawn from the study prematurely. The five patients who completed the six-week trial on amantadine showed improved performance on tests of memory acquisition in comparison with patients treated with benztropine. Global inspection of the results showed that only 36{\%} of the patients taking benztropine showed improvement in memory acquisition at the four- and six-week assessments, whereas 80{\%} of the amantadine users showed improvement at the four-week assessment. Analysis of covariance, however, revealed that the performance of the latter group decreased almost to baseline at six weeks, as an additional two of the remaining patients developed distressing EPSE.",
author = "McEvoy, {Joseph Patrick} and M. McCue and S. Freter",
year = "1987",
month = "1",
day = "1",
language = "English (US)",
volume = "9",
pages = "429--433",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "4",

}

TY - JOUR

T1 - Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia

AU - McEvoy, Joseph Patrick

AU - McCue, M.

AU - Freter, S.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Anticholinergic drugs have been shown to impair new memory acquisition. In a double-blind study, 22 chronically schizophrenic patients had the anticholinergic drugs that they had been taking to control the extrapyramidal side effects (EPSE) of neuroleptic drugs discontinued and were randomly assigned to treatment either with benztropine (an anticholinergic) or with amantadine (which has little or no anticholinergic effect). The EPSE of five of the ten patients assigned to amantadine could not be adequately controlled with that drug alone, and these patients were withdrawn from the study prematurely. The five patients who completed the six-week trial on amantadine showed improved performance on tests of memory acquisition in comparison with patients treated with benztropine. Global inspection of the results showed that only 36% of the patients taking benztropine showed improvement in memory acquisition at the four- and six-week assessments, whereas 80% of the amantadine users showed improvement at the four-week assessment. Analysis of covariance, however, revealed that the performance of the latter group decreased almost to baseline at six weeks, as an additional two of the remaining patients developed distressing EPSE.

AB - Anticholinergic drugs have been shown to impair new memory acquisition. In a double-blind study, 22 chronically schizophrenic patients had the anticholinergic drugs that they had been taking to control the extrapyramidal side effects (EPSE) of neuroleptic drugs discontinued and were randomly assigned to treatment either with benztropine (an anticholinergic) or with amantadine (which has little or no anticholinergic effect). The EPSE of five of the ten patients assigned to amantadine could not be adequately controlled with that drug alone, and these patients were withdrawn from the study prematurely. The five patients who completed the six-week trial on amantadine showed improved performance on tests of memory acquisition in comparison with patients treated with benztropine. Global inspection of the results showed that only 36% of the patients taking benztropine showed improvement in memory acquisition at the four- and six-week assessments, whereas 80% of the amantadine users showed improvement at the four-week assessment. Analysis of covariance, however, revealed that the performance of the latter group decreased almost to baseline at six weeks, as an additional two of the remaining patients developed distressing EPSE.

UR - http://www.scopus.com/inward/record.url?scp=0023279236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023279236&partnerID=8YFLogxK

M3 - Article

C2 - 2886223

AN - SCOPUS:0023279236

VL - 9

SP - 429

EP - 433

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 4

ER -